MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma
Authors:
- Monika E. HegiMHMonika E. Hegi
- Annie-Claire DiserensADAnnie-Claire Diserens
- Thierry GorliaTGThierry Gorlia
- Marie-France HamouMHMarie-France Hamou
- Nicolas de TriboletNTNicolas de Tribolet
- Michael WellerMWMichael Weller
- Johan M. KrosJKJohan M. Kros
- Johannes A. HainfellnerJHJohannes A. Hainfellner
- Warren MasonWMWarren Mason
- Luigi MarianiLMLuigi Mariani
- Jacoline E.C. BrombergJBJacoline E.C. Bromberg
- Peter HauPHPeter Hau
Top Cited Papers
- 10 March 2005
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (10) , 997-1003
Abstract
Epigenetic silencing of the MGMT (O6-methylguanine–DNA methyltransferase) DNA-repair gene by promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma who receive alkylating agents. We tested the relationship between MGMT silencing in the tumor and the survival of patients who were enrolled in a randomized trial comparing radiotherapy alone with radiotherapy combined with concomitant and adjuvant treatment with temozolomide. The methylation status of the MGMT promoter was determined by methylation-specific polymerase-chain-reaction analysis. The MGMT promoter was methylated in 45 percent of 206 assessable cases. Irrespective of treatment, MGMT promoter methylation was an independent favorable prognostic factor (PMGMT promoter, a survival benefit was observed in patients treated with temozolomide and radiotherapy; their median survival was 21.7 months (95 percent confidence interval, 17.4 to 30.4), as compared with 15.3 months (95 percent confidence interval, 13.0 to 20.9) among those who were assigned to only radiotherapy (P=0.007 by the log-rank test). In the absence of methylation of the MGMT promoter, there was a smaller and statistically insignificant difference in survival between the treatment groups. Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.Keywords
This publication has 14 references indexed in Scilit:
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- MGMT: its role in cancer aetiology and cancer therapeuticsNature Reviews Cancer, 2004
- Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with TemozolomideClinical Cancer Research, 2004
- Gene Silencing in Cancer in Association with Promoter HypermethylationNew England Journal of Medicine, 2003
- Promoter Hypermethylation of the DNA Repair Gene O 6 ‐ Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse AstrocytomasBrain Pathology, 2003
- Inactivation of the DNA-Repair GeneMGMTand the Clinical Response of Gliomas to Alkylating AgentsNew England Journal of Medicine, 2000
- DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.Journal of Clinical Oncology, 1998
- Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study.Journal of Clinical Oncology, 1998
- Methylation of Discrete Regions of the O 6 -Methylguanine DNA Methyltransferase (MGMT) CpG Island Is Associated with Heterochromatinization of the MGMT Transcription Start Site and Silencing of the GeneMolecular and Cellular Biology, 1997
- O6-Alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implicationsJournal of Neuro-Oncology, 1994